Viatris Inc. has announced positive top-line results from the VEGA-3 trial, the second pivotal Phase 3 study evaluating MR-141 (phentolamine ophthalmic solution 0.75%) for treating presbyopia. The trial met its primary and all secondary endpoints, demonstrating rapid and sustained improvement in near visual acuity without compromising distance vision. The safety profile was consistent with previous clinical trials, with no treatment-related serious adverse events reported. The study involved 545 patients and showed significant improvements in visual acuity compared to placebo. Viatris plans to submit an application to the U.S. FDA in the second half of 2025. Results from this study have already been presented.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.